Form 4 Kymera Therapeutics, For: Oct 29 Filed by: Mainolfi Nello
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics (NASDAQ:KYMR) was given a new $80.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- Kymera Therapeutics (NASDAQ:KYMR) was given a new $90.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.MarketBeat
- Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 DegraderGlobeNewswire
- Kymera Therapeutics to Participate in Upcoming December Investor ConferencesGlobeNewswire
- Kymera Therapeutics, Inc. (KYMR) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]Seeking Alpha
KYMR
Earnings
- 11/4/25 - Miss
KYMR
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/5/25 - Form SCHEDULE
- 11/4/25 - Form 10-Q
- KYMR's page on the SEC website